Our Passion

Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst AG. After that, he became General Manager of the successful and renowned companies Servier Deutschland and Amgen GmbH in Munich. Dr. Frank Mathias was Chief Executive Officer of the Medigene AG from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer taken the responsibility for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies. Since April 1st, 2016 Dr. Frank Mathias has been Chief Executive Officer of Rentschler Biopharma SE.

Christiane Bardroff studied biotechnology and chemical engineering at Emden University of Applied Sciences, Germany and Zhejiang University of Science and Technology in Hangzhou, China. She joined Rentschler Biopharma as SVP Client Program Management in February 2022 and, since May 2022, also has been responsible for Clinical and Commercial Manufacturing at the Laupheim site as SVP Clinical and Commercial Manufacturing. Prior to joining Rentschler Biopharma, Ms. Bardroff was responsible for the construction of Teva Biotech’s highly automated, large-scale biotechnology production facility in Ulm, Germany. In her role as Senior Director Operations Biotech, she led the site leadership team and was part of Teva Biotech’s global leadership team. Prior to that, she worked for many years at Roche; where she gained strong experience in the production of various biotechnology products, as well as in automation, IT and project management. Christiane Bardroff has been Chief Operating Officer of Rentschler Biopharma SE since 1 December 2022.

Alexander Dettmer studied in Boston, MA, USA as well as in Singapore and holds a Diploma in Economics and Business Administration (Lic. Oec.) from the University of St. Gallen (HSG), Switzerland. Prior to joining Rentschler Biopharma, Mr. Dettmer successfully held several senior leadership positions within the Fresenius SE & Co. KGaA group, which he joined in 2005. His last role was Senior Vice President Corporate Business Development/M&A, where he led the broader M&A team that managed M&A transaction processes. Previous to that, he was CFO of Fresenius Kabi's Medical Devices Division, Executive VP Finance, Procurement & HR, where his responsibilities included financial planning, controlling, compliance, strategic purchasing and product partnering. Before that, he was CFO and Managing Director at Fresenius Biotech GmbH (now: Neovii Biotech).

Dr. Christian Schetter studied biology and earned his Ph.D. in molecular biology at the Institute of Genetics, University of Cologne, Germany. Prior to joining Rentschler Biopharma, Dr. Christian Schetter was Managing Director at Arix Bioscience plc, UK, responsible for investment decisions as well as scientific evaluations and served in support functions for portfolio companies. As CEO of Rigontec GmbH (now MSD / Merck & Co., USA), he was responsible for the successful acquisition by MSD and continued to serve as CEO of Rigontec GmbH, an MSD Company, after closing of the transaction. Previously, he was President & CEO for Fresenius Biotech GmbH (now Neovii Biotech) and Senior VP as well as Managing Director of Coley Pharmaceutical Group (now Pfizer). Dr. Schetter is also Non-Executive Chairman of STipe Therapeutics and Chairman of the Supervisory Board of Eternygen GmbH. Dr. Schetter has held several scientific positions, including at Scripps Research Institute, La Jolla, CA, USA, and as Senior Research Associate at the Max Planck Institute for Biochemistry, Martinsried, Germany. Dr. Christian Schetter has been Chief Scientific Officer of Rentschler Biopharma SE since September 15, 2021.

Federico Pollano studied biology at Bielefeld University, and at the German Primate Center, Goettingen, Germany. Prior to joining Rentschler Biopharma, he was Global Director Contract Manufacturing and Business Development at Polpharma Biologics. While there, he established the CDMO business and was responsible for in- and out-licensing platform technologies, in addition to setting up a large-scale cell culture facility. Prior to his work at Polpharma, Federico Pollano was Managing Director at Richter-Helm-BioTec and Executive Manager Pharmaceuticals at Helm Pharmaceuticals, the generics business of Helm AG. Earlier in his career, he was Head of Business Development and Member of the Management Board of BioGeneriX AG and worked at Glaxo Wellcome GmbH for nearly ten years in positions of increasing responsibility. As Senior Vice President Business Development of Rentschler Biopharma SE, Federico Pollano has been responsible for made-to-measure client services since March 2018. As of February 2023, he has been a member of the Extended Executive Team (EET).

Tobias Glueck studied Business Administration at Weserbergland University of Applied Sciences, Germany. He joined Rentschler Biopharma from Novartis Germany GmbH, where he served as Managing Director People & Organization, covering the full HR scope of the Pharma Business Unit, and led all cross-divisional HR activities in Germany. He drove new corporate culture initiatives and initiated pilot programs to improve employee experience. Prior to that, Tobias Glueck was Vice President Human Resources at Cameron, a SLB company. For this leading oilfield services company, he was based in the U.S. with HR responsibility for sites of various business units around the globe. In these positions, he successfully drove recruitment and retention activities, oversaw various transformation projects, and implemented and improved talent development programs. Tobias Glueck has been Senior Vice President Human Relations of Rentschler Biopharma since October 2022 and a member of the Extended Executive Team (EET) since February 2023.